Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1514-1519

  Heald, Alison E ^a   Hsyu, Poe H ^b   Yuen, Geoffrey J ^b   Robinson, Peggy ^a   Mydlow, Patricia ^b   Bartlett, John A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0029952016     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1514     Document Type: Article

References (23)

1. Bartlett, J. A., S. L. Benoit, V. A. Johnson, J. B. Quinn, G. E. Sepulveda, C. Ehmann, C. Tsoukas, M. A. Fallon, P. L. Self, M. Rubin, and the North American HIV Working Party. The safety and efficacy of lamivudine plus zidovudine versus zalcitabine plus zidovudine in the treatment of zidovudine-experienced HIV-infected patients. Ann. Intern. Med., in press.
2. Bourgoignie, J. J., R. Meneses, C. Ortiz, D. Jaffe, and V. Pardo. 1988. The clinical spectrum of renal disease associated with human immunodeficiency virus. Am J. Kidney Dis. 12:131-137.
3. Coates, J. A. V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. 1992 The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro Antimicrob. Agents Chemother. 36:202-205.
4. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
5. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
6. Glassock, R. J., A. H. Cohen, G. Danovitch, and K. P. Parsa. 1990. Human immunodeficiency virus (HIV) infection and the kidney Ann Intern. Med 112:35-49.
7. Harker, A. J., G. L. Evans, A. E. Hawley, and D. M. Morris. 1994. High-performance liquid chromatography assay for 2′-deoxy-3′-thiacytidine in human serum. J Chromatogr. B Biomed. Appl. 657:227-232.
8. Hart, G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Gray, R. E. Boehme, and J. M. Cameron. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA porymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694
9. Horton, C. M., G. J. Yuen, P. E. Pivarnik, D. M. Mikolich, A. E. Fisher, K. Rana, P. K. Mydlow, and M. N. Dudley. 1994. Pharmacokinetics of oral lamivudine administered alone and with oral zidovudine in asymptomatic patients with human immunodeficiency virus (HIV) infection. Clin Pharmacol. Ther 55:198.
10. Humphreys, M. H., and P. Y. Schoenfeld. 1987. Renal complications in patients with the acquired immune deficiency syndrome (AIDS). Am. J. Nephrol. 7:1-7.
11. Katlama, C., and the European Lamivudine HIV Working Group. 1995. Combination 3TC/ZDV vs ZDV monotherapy in ZDV naive HIV-1 positive patients with a CD4 of 100-400 cell/mm3, abstr. LB31, p. 173. Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C.
12. Moore, K., R. Raasch, G. Yuen, J. Eron, D. Martin, and E. Hussey. 1995. Pharmacokinetics of lamivudine (3TC) administered alone and with oral trimethoprim plus sulfamethoxazole in patients with human immunodeficiency virus infection. Clin Pharmacol. Ther., in press.
13. Morris, D. M., and K. Selinger. 1994. Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching. J. Pharm. Biomed. Anal. 12:255-264.
14. Pluda, J. M., T. P. Cooley, J. S. G. Montaner, L. E. Shay, N. E. Reinhalter, S. N. Warthan, J. Ruedy, H. M. Hirst, C. A. Vicary, J. B. Quinn, G. J. Yuen, M. A. Wainburg, M. Rubin, and R. Yarchoan. 1995. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1438-1447.
15. Rana, K. Z., C. M. Horton, G. J. Yuen, P. E. Pivarnik, D. M. Mikolich, A. E. Fisher, P. K. Mydlow, and M. N. Dudley. 1994. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals, abstr. A62, p. 83. Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D C.
16. Rao, T. K. S., and E. A. Friedman. 1988 Renal syndromes in the acquired immunodeficiency syndrome (AIDS): lessons learned from analysis over 5 years. Artif. Organs 12:206-209.
17. Rao, T. K. S., E. A. Friedman, and A. D. Nicastri. 1987. The types of renal disease in the acquired immunodeficiency syndrome. N. Engl. J Med 316: 1062-1068.
18. Schinazi, R. F., C. K. Chu, A. Peck, A. McMillan, R. Mathis, D. Cannon, L. S. Jeong, J. W. Beach, W. B. Choi, S. Yeola, and D. C. Liotta. 1992. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:672-676.
19. Soudeyns, H., X. J. Yao, Q. Gao, B. Belleau, J. L. Kraus, N. Nguyen-Ba, B. Spira, and M. A. Wainberg. 1991. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 35:1386-1390.
20. Staszewski, S., and the European Lamivudine HIV Working Group. 1995. Combination 3TC/ZDV vs ZDV monotherapy in ZDV experienced HIV-1 positive patients with a CD4 of 100-400 cells/mm3, abstr. LB32, p. 173. Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infection, Washington, D.C.
21. van Leeuwen, R., C. Katlama, V. Kitchen, C. A. B. Baucher, R. Tubiana, M. McBride, D. Ingrand, J. Weber, A. Hill, H. McDade, and S. A. Danner. 1995. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1166-1171.
22. van Leeuwen, R., J. M. A. Lange, E. K. Hussey, K. H. Donn, S. T. Hall, A. J. Harker, P, Jonker, and S. A. Danner. 1992. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 6:1471-1475
23. Yuen, G. J., D. M. Morris, P. K. Mydlow, S. Haidar, S. T. Hall, and E. K. Hussey. 1995. The pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine (3TC). J. Clin. Pharmacol. 35:1174-1180.